Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Autolus Therapeutics Plc ADR (AUTL)

Autolus Therapeutics Plc ADR (AUTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 380,514
  • Shares Outstanding, K 266,094
  • Annual Sales, $ 10,120 K
  • Annual Income, $ -220,660 K
  • EBIT $ -230 M
  • EBITDA $ -222 M
  • 60-Month Beta 2.06
  • Price/Sales 35.50
  • Price/Cash Flow N/A
  • Price/Book 0.87

Options Overview Details

View History
  • Implied Volatility 345.21% ( -59.46%)
  • Historical Volatility 103.89%
  • IV Percentile 94%
  • IV Rank 53.17%
  • IV High 637.10% on 04/07/25
  • IV Low 13.86% on 09/12/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 1,266
  • Volume Avg (30-Day) 312
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 7,070
  • Open Int (30-Day) 5,293

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.24
  • Number of Estimates 4
  • High Estimate -0.19
  • Low Estimate -0.29
  • Prior Year -0.24
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1050 +29.41%
on 04/11/25
2.0150 -29.03%
on 03/20/25
-0.3900 (-21.43%)
since 03/17/25
3-Month
1.1050 +29.41%
on 04/11/25
2.4300 -41.15%
on 01/27/25
-0.7900 (-35.59%)
since 01/17/25
52-Week
1.1050 +29.41%
on 04/11/25
5.2500 -72.76%
on 04/18/24
-3.4100 (-70.45%)
since 04/17/24

Most Recent Stories

More News
Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

AUTL : 1.4300 (+5.93%)
Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

AUTL : 1.4300 (+5.93%)
Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

AUTL : 1.4300 (+5.93%)
Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

AUTL : 1.4300 (+5.93%)
Autolus Therapeutics to Participate in Upcoming Investor Conferences

AUTL : 1.4300 (+5.93%)
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

AUTL : 1.4300 (+5.93%)
Autolus Therapeutics Provides Business Updates and 2025 Overview

AUTL : 1.4300 (+5.93%)
The Immunotherapy Boom: What It Means for the Future of Cancer Treatment

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Immunotherapy is revolutionizing oncology by harnessing the power of the immune system to fight cancer...

ONCY : 0.5610 (-1.23%)
AUTL : 1.4300 (+5.93%)
IOVA : 3.06 (-0.33%)
ABBV : 172.99 (+0.76%)
ONC.TO : 0.77 (-1.28%)
IBRX : 2.47 (-0.40%)
Autolus Therapeutics Presents Key Findings on obe-cel at the 2024 ASH Annual Meeting

Autolus Therapeutics presents data at ASH 2024 on obe-cel for adult relapsed/refractory B-ALL, highlighting clinical outcomes and cost efficiency.Quiver AI SummaryAutolus Therapeutics plc announced its...

AUTL : 1.4300 (+5.93%)
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

AUTL : 1.4300 (+5.93%)

Business Summary

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London,...

See More

Key Turning Points

3rd Resistance Point 1.6550
2nd Resistance Point 1.5700
1st Resistance Point 1.5000
Last Price 1.4300
1st Support Level 1.3450
2nd Support Level 1.2600
3rd Support Level 1.1900

See More

52-Week High 5.2500
Fibonacci 61.8% 3.6666
Fibonacci 50% 3.1775
Fibonacci 38.2% 2.6884
Last Price 1.4300
52-Week Low 1.1050

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar